Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study Phase III, Multicenter, Prospective, Open to Evaluate the Efficacy and Tolerability of the Combination Use of Passiflora Incarnata L, Crataegus Oxyacantha and Salix Alba L in Mild and Moderate Anxiety

NCT00944268 is registered in ClinicalTrials.gov with Ativus Farmaceutica Ltda as lead sponsor.

NCT NCT00944268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00944268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study Phase III, Multicenter, Prospective, Open to Evaluate the Efficacy and Tolerability of the Combination Use of Passiflora Incarnata L, Crataegus Oxyacantha and Salix Alba L in Mild and Moderate Anxiety
Lead sponsor
Ativus Farmaceutica Ltda
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2009
Completion date
January 31, 2010
Enrollment
124 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety, efficacy, tolerability